Shandong Weigao Group Medical Polymer Company Limited (Weigao Group) disclosed that it repurchased 16,400 H-shares on 6 October 2026 through on-market transactions on the Hong Kong Stock Exchange, paying an aggregate HKD 53,394. The highest price per share was HKD 3.26 and the lowest HKD 3.255, resulting in a volume-weighted average repurchase price of approximately HKD 3.2557.

Following the transaction, the company’s issued share capital (excluding treasury shares) declined marginally by 0.0004% to 4.46 billion shares, while treasury shares increased to 66.78 million. The total number of issued shares remained unchanged at 4.52 billion.

The buyback forms part of the mandate approved by shareholders on 29 May 2026, which authorises repurchases of up to 446.46 million shares. Including the latest transaction, Weigao Group has repurchased 9.46 million shares, representing 2.12% of the issued share capital on the mandate date.

In line with Hong Kong listing rules, the company is subject to a 30-day moratorium on issuing, selling or transferring shares following this repurchase, ending on 6 November 2026. The board confirmed that all repurchase activities complied with applicable regulations and that all requirements relating to treasury shares have been met.